Citigroup Raises JNJ Price Target to $303 on Strong Growth Outlook

Citigroup has reaffirmed its "Buy" rating for Johnson & Johnson (JNJ) while raising its price target from $298.00 to $303.00, a 1.68% increase. The adjustment, made on October 5, 2026, reflects the firm's positive outlook on JNJ's growth prospects within the healthcare sector. Analyst Joanne Wuensch emphasized the company's ability to navigate market challenges and leverage its diverse product offerings, particularly in pharmaceuticals and medical devices.

Despite the bullish rating, GuruFocus's GF Value™ suggests that JNJ is currently 30.3% overvalued, with a current price of $252.83 compared to its intrinsic value of $194.07. The stock's price-to-earnings (P/E) ratio of 29.3x is also higher than its 5-year median of 24.43x, further indicating potential overvaluation. However, JNJ's GF Score™ of 83/100 highlights strong financial performance, particularly in profitability and growth, though its momentum rank is lower.

The mixed signals extend to institutional and insider activity. While 24 gurus hold shares of JNJ, with 5 adding to their positions, 14 have trimmed their holdings. Insider selling has amounted to $67,779,550 over the past three months, raising concerns about the company's near-term outlook. Investors are advised to exercise caution given these contrasting indicators.